Operose Advisors’s Repligen RGEN Stock Holding History

Operose Advisors’s Portfolio RGEN Stock Details RGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-620	Closed	-$98.6K	–	704
2023 Q3	$98.6K	Buy	+620	New	+$101K	0.04%	211

Other funds holding RGEN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Operose Advisors's RGEN Position: Q4 2023 in Review

Operose Advisors sold out of Repligen (RGEN) in Q4 2023, closing a stake of 620 shares — an estimated $98.6K sold.

Operose Advisors first reported a position in RGEN in Q3 2023 and held it in 1 quarter. The position peaked at $98.6K in Q3 2023. 466 funds tracked by Wall St. Rank hold RGEN as of Q4 2023.

Operose Advisors reported no remaining Repligen position as of Q4 2023 after selling out during the quarter.
Operose Advisors sold 620 Repligen shares in Q4 2023, an estimated $98.6K.
Operose Advisors first reported a position in Repligen in Q3 2023 and held it in 1 quarter.
Operose Advisors's Repligen position peaked at $98.6K in Q3 2023.
466 funds tracked by Wall St. Rank held Repligen as of Q4 2023.

Based on Operose Advisors's 13F filing for Q4 2023, filed 12 Feb 2024.